Oncopeptides AB listed on Nasdaq Stockholm main market
February 22, 2017
Oncopeptides AB (publ) hereby announces the outcome relating to the offering to acquire shares in the company and the listing on Nasdaq Stockholm. The offering attracted strong interest among Swedish and international investors and the offering was oversubscribed several times.
By continuing on the site you accept our terms and conditions for cookies. More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.